National Institute on Drug Abuse; Notice of Closed Meetings, 8096-8097 [E9-3438]

Download as PDF 8096 Federal Register / Vol. 74, No. 34 / Monday, February 23, 2009 / Notices jlentini on PROD1PC65 with NOTICES commercialize the above invention. Please contact Dr. Joseph Shiloach at joseph.shiloach@nih.gov or 301–496– 9719 for more information. Licensing Contact: Jeffrey A. James, PhD; 301–435–5474; jeffreyja@mail.nih.gov. Teniae Coli Guided Navigation and Registration for Virtual Colonoscopy Description of Technology: This invention describes a more sensitive and efficient method for colon cancer screening using the teniae coli as an anatomical reference. Most computed tomographic colonography (CTC) protocols for colon cancer screening require that a patient is scanned in both the supine and prone positions for increased sensitivity; as a result, a reference system between scans is necessary for lesion matching. The teniae coli are three equal-distanced bands of longitudinal smooth muscle on the surface of the colon between the appendix and the sigmoid colon. These muscles can be used as anatomical landmarks to derive a coordinate system to better localize and register the corresponding supine and prone positions of a CTC study. The inventors have devised a semi-automated system for extracting data from the teniae coli and defining coordinate systems based on them. The invention allows for more detailed detection of anatomical features for surgical planning, better camera orientation and virtual protocols, more efficient lesion registration, and precise record keeping. The algorithm has been used successfully to correctly localize several polyps to the same circumferential position in both supine and prone scans of a CTC study. Applications: • Positioning virtual cameras for navigating a single dataset. • Synchronizing virtual cameras for virtual colonoscopic navigation. • Predicting lesion candidates in a bound region for both 2D and 3D reading paradigms. • Automatic polyp matching between scans for CAD applications. Development Status: Late stage. Inventors: Hui-Yang Huang (CC), Ronald M. Summers (CC), Dave R. Roy (OD). Publication: A Huang, DA Roy, RM Summers, M Franaszek, N Petrick, JR Choi, PJ Pickhardt. Teniae coli-based circumferential localization system for CT colonography: feasibility study. Radiology 2007 May;243(2):551–560. Patent Status: • U.S. Patent Application No. 11/ 436,889 filed May 17, 2006 (HHS Reference No. E–084–2006/0–US–01). • No foreign rights available. Licensing Status: Available for licensing. VerDate Nov<24>2008 16:31 Feb 20, 2009 Jkt 217001 Method and Apparatus for Performing Multiple Simultaneous Manipulations of Biomolecules in a Two-Dimensional Array Description of Technology: This technology concerns a method and apparatus for accomplishing and/or facilitating the analysis of multiple biomolecules separated in a twodimensional array, such as gel, membrane, tissue biopsy, etc. The invention employs a separator, termed an External Movement Inhibitor Device, that allows biomolecules to be transferred from an array such as those listed above to another support system while maintaining the two-dimensional spatial relationship of the biomolecules as in the array. The biomolecules can subsequently be subjected to various manipulations such as amplification, reverse transcription, labeling, cloning, etc., after which multiple wellestablished methods for quantitative and qualitative analysis can be used. Applications: • Two dimensional nucleic acid analysis. • Two dimensional proteomic analysis. • Histology/Pathology. Advantages: Allows for simultaneous 2D analysis of nucleic acids and proteins. Development Status: In vitro data can be provided upon request. Market: • Histology/Pathology of tissue samples. • Tissue arrays. • Nucleic acid and proteomic analysis. Inventors: Michael R. Emmert-Buck et al. (NCI). Patent Status: • International Patent Application No. PCT/US03/37208 filed 20 Nov 2003 (HHS Ref. No. E–339–2002/0–PCT–02). • U.S. Patent Application No. 10/535,521 filed 18 May 2005 (HHS Reference No. E–339–2002/0–US–03). Licensing Status: Available for licensing. Licensing Contact: Kevin W. Chang, PhD; 301–435–5018, changke@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Laboratory of Pathology and Urologic Oncology Branch, Center for Cancer Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an external movement PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 inhibitor device for spatially restricted PCR amplification of nucleic acids. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. Dated: February 10, 2009. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E9–3811 Filed 2–20–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA– K Conflicts—SEP. Date: March 17, 2009. Time: 4:30 p.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, N.W., Washington, DC 20037. Contact Person: Kristen V. Huntley, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, 301–435–1433, huntleyk@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Medications Development Centers. Date: March 19–20, 2009. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Sofitel Hotel, 806 15th Street, Washington, DC 20005. Contact Person: Scott Chen, PhD, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892, 301–443–9511, chensc@mail.nih.gov. E:\FR\FM\23FEN1.SGM 23FEN1 Federal Register / Vol. 74, No. 34 / Monday, February 23, 2009 / Notices Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; AIDSRelated CEBRA Review. Date: March 20, 2009. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: 6101 Executive Blvd, 220 Rockville, MD 20852, (Virtual Meeting). Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; I/ START Review. Date: March 27, 2009. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Conference Grant Application Review. Date: March 27, 2009. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1431, mgreen1@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: February 11, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–3438 Filed 2–20–09; 8:45 am] jlentini on PROD1PC65 with NOTICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice Jkt 217001 applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel, Minority Biomedical Research Score Applications. Date: March 9–10, 2009. Time: 3 p.m. to 10 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, Room 3AN18, 45 Center Drive, Bethesda, MD 20892. (Virtual Meeting) Contact Person: Meredith D. TempleO’Connor, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12C, Bethesda, MD 20892, 301–594– 2772, templeocm@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: February 13, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–3704 Filed 2–20–09; 8:45 am] Dated: February 12, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–3589 Filed 2–20–09; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of General Medical Sciences; Notice of Closed Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES 16:31 Feb 20, 2009 Name of Committee: National Institute on Alcohol Abuse and Alcoholism, Special Emphasis Panel, Mechanisms Underlying Alcohol Treatment. Date: March 17, 2009. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Katrina L Foster, PhD, Scientific Review Officer, National Inst. on Alcohol Abuse & Alcoholism, National Institutes of Health, 5635 Fishers Lane, Rm. 2019, Rockville, MD 20852, 301–443–4032, katrina@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS) National Institutes of Health BILLING CODE 4140–01–M VerDate Nov<24>2008 is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 8097 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of General Medical Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis E:\FR\FM\23FEN1.SGM 23FEN1

Agencies

[Federal Register Volume 74, Number 34 (Monday, February 23, 2009)]
[Notices]
[Pages 8096-8097]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-3438]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA-K Conflicts--SEP.
    Date: March 17, 2009.
    Time: 4:30 p.m. to 6:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz Carlton Hotel, 1150 22nd Street, N.W., Washington, 
DC 20037.
    Contact Person: Kristen V. Huntley, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401, 301-435-1433, huntleyk@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Medications Development Centers.
    Date: March 19-20, 2009.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sofitel Hotel, 806 15th Street, Washington, DC 20005.
    Contact Person: Scott Chen, PhD, Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 
220, MSC 8401, Bethesda, MD 20892, 301-443-9511, 
chensc@mail.nih.gov.


[[Page 8097]]


    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; AIDS-Related CEBRA Review.
    Date: March 20, 2009.
    Time: 1 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: 6101 Executive Blvd, 220 Rockville, MD 20852, (Virtual 
Meeting).
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; I/START Review.
    Date: March 27, 2009.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Conference Grant Application Review.
    Date: March 27, 2009.
    Time: 1 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Mark R. Green, PhD, Deputy Director, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1431, mgreen1@nida.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: February 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-3438 Filed 2-20-09; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.